Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ACTILYSE 2 mg is substantial. |
Clinical Added Value
| minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE. |
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
5gaW2VBCXDrYXVck
Listen
Français